Abstract
Entecavir and tenofovir disoproxil fumarate are potent and effective antiviral drugs that now represent recommended treatment options for chronic HBV infection. However, no or very limited clinical evidence is currently available on these drugs for the management of HBV reactivation in patients with haematological malignancies. Herein, we report a case of HBV reactivation in a patient with non-Hodgkin's lymphoma following a rituximab-based regimen, and who was successfully treated with a combination antiviral treatment including entecavir and tenofovir disoproxil fumarate.
MeSH terms
-
Adenine / analogs & derivatives*
-
Adenine / therapeutic use
-
Antibodies, Monoclonal, Murine-Derived / therapeutic use*
-
Antiviral Agents / therapeutic use*
-
Drug Combinations
-
Female
-
Guanine / analogs & derivatives*
-
Guanine / therapeutic use
-
Hepatitis B virus / physiology
-
Hepatitis B, Chronic / drug therapy*
-
Humans
-
Lymphoma, Non-Hodgkin
-
Middle Aged
-
Organophosphonates / therapeutic use*
-
Rituximab
-
Tenofovir
-
Virus Activation
Substances
-
Antibodies, Monoclonal, Murine-Derived
-
Antiviral Agents
-
Drug Combinations
-
Organophosphonates
-
Rituximab
-
entecavir
-
Guanine
-
Tenofovir
-
Adenine